Sophiris Bio (NASDAQ:SPHS) : Traders are bullish on Sophiris Bio (NASDAQ:SPHS) as it has outperformed the S&P 500 by a wide margin of 21.28% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.02%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.44% in the last 1 week, and is up 23.23% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 193.98% from its 1 Year high price. On Nov 12, 2015, the shares registered one year high at $3.85 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $1.62 and the 200 Day Moving Average price is recorded at $1.60.
The stock has recorded a 20-day Moving Average of 23.08% and the 50-Day Moving Average is 68.52%.
Sophiris Bio (NASDAQ:SPHS): On Fridays trading session , Opening price of the stock was $2.56 with an intraday high of $2.59. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $2.26. However, the stock managed to close at $2.44, a loss of 2.01% for the day. On the previous day, the stock had closed at $2.49. The total traded volume of the day was 1,307,965 shares.
In an insider trading activity, The director, of Sophiris Bio Inc., Ekman Lars had unloaded 9,663 shares at $0.47 per share in a transaction on December 18, 2014. The total value of transaction was $4,542. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.